Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients (EASIE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT00751114
First received: September 10, 2008
Last updated: September 3, 2012
Last verified: September 2012

September 10, 2008
September 3, 2012
November 2008
July 2011   (final data collection date for primary outcome measure)
HbA1c: Change From Baseline to Study Endpoint [ Time Frame: baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14 ] [ Designated as safety issue: No ]
Change in HbA1c from baseline to study endpoint defined as the last available HbA1c value measured during the 24-week treatment period.
HbA1c [ Time Frame: Recorded at baseline (week 0), visit 11 (week 12) and visit 14 (week 24) ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00751114 on ClinicalTrials.gov Archive Site
  • HbA1c Response Rate: Percentage of Patients Who Reach the Target of HbA1c < 7% at Study Endpoint [ Time Frame: study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14 ] [ Designated as safety issue: No ]
  • HbA1c Response Rate: Percentage of Patients Who Reach the Target of HbA1c < 6.5% at Study Endpoint [ Time Frame: study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14 ] [ Designated as safety issue: No ]
  • Self-monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint [ Time Frame: baseline (week 0), study endpoint: visit 14 (week 24) or visit 12 (week 16) or visit 11 (week 12) or visit 8 (week 6) depending on last available value ] [ Designated as safety issue: No ]

    SMFPG mean = mean of the fasting plasma glucose values recorded on the 6 consecutive days before the visit (at least 3 values needed).

    Study endpoint was defined as the last available SMFPG mean value collected on-treatment.

    Change= study endpoint - baseline

  • 7-point Plasma Glucose Profile: Change From Baseline to Study Endpoint [ Time Frame: baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14 ] [ Designated as safety issue: No ]

    7-point plasma glucose recorded before and after breakfast, before and after lunch, before and after dinner and at bedtime.

    Change = study endpoint - baseline.

  • Insulin Dose in the Insulin Glargine Group [ Time Frame: visit 4 (week 2), visit 8 (week 6), visit 11 (week 12), visit 12 (week 16), visit 14 (week 24), first dose received defined as first available value, study endpoint defined as last available value ] [ Designated as safety issue: No ]
    Daily dose at the face-to-face visits.
  • Lipid Profile: Change From Baseline to Study Endpoint [ Time Frame: baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14 ] [ Designated as safety issue: No ]
  • Change in Body Weight From Baseline to Study Endpoint [ Time Frame: baseline (week 0), study endpoint: visit 14 (week 24) or visit 12 (week 16) or visit 11 (week 12) or visit 8 (week 6) depending on last available value ] [ Designated as safety issue: Yes ]
  • Number of Patients With at Least One Episode of Symptomatic Hypoglycemia [ Time Frame: During the treatment phase (24 weeks) plus 7 days after last dose ] [ Designated as safety issue: Yes ]
    Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia confirmed or not by a plasma glucose measurement <= 70mg/dL [3.9 mmol/L]
  • Number of Patients With at Least One Episode of Severe Symptomatic Hypoglycemia [ Time Frame: During the treatment phase (24 weeks) plus 7 days after last dose ] [ Designated as safety issue: Yes ]
    Severe symptomatic hypoglycemia was defined as an event with clinical symptoms which required assistance of another person and with either a Plasma Glucose level < 36 mg/dL (2 mmol/L) or with a prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration
  • Plasma glucose profile [ Time Frame: Prior to baseline (week 0), visit 11 (week 12) and visit 14 (week 24) ] [ Designated as safety issue: No ]
  • Self-monitored FPG [ Time Frame: At baseline (week 0), visit 8 (week 6), visit 11 (week 12), visit 12 (week 16) and visit 14 (week 24) ] [ Designated as safety issue: No ]
  • Weight [ Time Frame: At baseline (week 0), visit 8 (week 6), visit 11 (week 12), visit 12 (week 16) and visit 14 (week 24) ] [ Designated as safety issue: No ]
  • Insulin dose in the insulin glargine group [ Time Frame: At visit 4 (week 2), visit 8 (week 6), visit 11 (week 12), visit 12 (week 16) and visit 14 (week 24) ] [ Designated as safety issue: No ]
  • Hypoglycemia [ Time Frame: All across the study ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: All across the study ] [ Designated as safety issue: No ]
  • Vital signs [ Time Frame: All across the study ] [ Designated as safety issue: No ]
  • Laboratory data [ Time Frame: All across the study ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients
Superiority Study of Insulin Glargine Over Sitagliptin in Insulin-naïve Patients With Type 2 Diabetes Treated With Metformin and Not Adequately Controlled

The primary objective was to demonstrate the superiority of insulin glargine over sitagliptin in reducing Glycosylated Hemoglobin A1c (HbA1c) from baseline to the end of the treatment period.

Secondary objective was to assess the effect of insulin glargine in comparison with sitagliptin on:

  • HbA1c level
  • Fasting Plasma Glucose (FPG)
  • 7-point plasma glucose (PG) profiles
  • Percentage of patients with HbA1c <7% and <6.5%

Safety objectives consisted of:

  • Hypoglycemia occurrence
  • Body weight
  • Overall safety
Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
  • Drug: Insulin Glargine
    Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL).
    Other Name: Lantus®
  • Drug: Sitagliptin
    Oral administration. 100 mg film-coated tablets.
    Other Name: Januvia®
  • Drug: Metformin
    Patients continued with metformin as usual oral anti-diabetic treatment.
  • Experimental: Insulin Glargine
    Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL<FPG≤100mg/dL (3.9mmol/L<FPG≤5.5mmol/L).
    Interventions:
    • Drug: Insulin Glargine
    • Drug: Metformin
  • Active Comparator: Sitagliptin
    Dose of 100 mg once a day administered with or without food.
    Interventions:
    • Drug: Sitagliptin
    • Drug: Metformin
Aschner P, Chan J, Owens DR, Picard S, Wang E, Dain MP, Pilorget V, Echtay A, Fonseca V; EASIE investigators. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet. 2012 Jun 16;379(9833):2262-9. doi: 10.1016/S0140-6736(12)60439-5. Epub 2012 Jun 9. PubMed PMID: 22683131.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
515
July 2011
July 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • With type 2 diabetes diagnosed for at least 6 months,
  • Not previously treated with insulin,
  • On metformin for at least 3 months and a stable minimal dose of 1 g/day for at least 2 months
  • HbA1c ≥ 7 and < 11 %,
  • Body Mass Index (BMI) between 25 and 45 kg/m² inclusively,
  • Ability and willingness to perform plasma glucose (PG) monitoring using the Sponsor-provided PG meter and to complete the patient diary,
  • Signed informed consent obtained prior any study procedures,
  • Willingness and ability to comply with the study protocol.

Exclusion Criteria:

  • Treatment with oral antidiabetic drugs other than metformin within the last 3 months,
  • Previous treatment with the combination of metformin + sulfonylurea for more than 1 year,
  • Previous treatment with Glucagon Like Peptide-1 (GLP-1) agonists or DiPeptidyl Peptidase (DPP) IV inhibitors,
  • FPG (assessed by central laboratory measurement) ≥ 280 mg/dL (15.4 mmol/L),
  • Diabetes other than type 2 diabetes (e.g. secondary to pancreatic disorders, drug or chemical agents intake...),
  • Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method),
  • In-patient care,
  • Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy occurrence in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during the study (an optic fundus examination should have been performed within the 2 years prior to study entry),
  • Impaired renal function: serum creatinine ≥ 1.5 mg/dL (≥ 133µmol/L) or ≥ 1.4 mg/dL (≥ 124 µmol/L) in men and women, respectively,
  • History of sensitivity to the study drugs or to drugs with a similar chemical structure,
  • Impaired hepatic function: alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 3 x upper limit of normal range,
  • Treatment with systemic corticosteroids within the 3 months prior to study entry or likelihood of requiring treatment during the study that are not permitted during the study (exception: in case of chronic adrenal insufficiency, systemic glucosteroids are accepted only if the disease is stable and the treatment dose stable for at least 3 months before study entry),
  • Alcohol or drug abuse within the last year,
  • Night shift worker,
  • Presence of any condition (medical, psychological, social or geographical), current or anticipated that the investigator feels would compromise the patient's safety or limit the patient successful participation in the study,
  • Treatment with weight loss medications (e.g. sibutramine, orlistat, rimonabant) within the last 3 months,
  • Participation in another clinical trial within the month prior to visit 1,
  • History of pancreatitis.
Both
35 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Austria,   Brazil,   Colombia,   Egypt,   Greece,   Hong Kong,   India,   Israel,   Korea, Republic of,   Lebanon,   Mexico,   Netherlands,   Portugal,   Spain,   Turkey,   United Kingdom
 
NCT00751114
LANTU_C_02761, 2008-000516-32
Not Provided
Sanofi
Sanofi
Not Provided
Study Director: Clinical Sciences & Operations Sanofi
Sanofi
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP